



Hope Funds for Cancer Research

Press Release

Hope Funds SAC Chair Bryan R.G. Williams Honored

For Immediate Release

Media Contact:

John A. Wells

212-769-2170

media@hope-funds.org

Newport, RI - November 14, 2019 - The Hope Funds for Cancer Research, dedicated to advancing innovative research for the most difficult-to-treat cancers, congratulates its Scientific Advisory Chair, Professor Bryan R.G. Williams, for being awarded the 2019 Distinguished Service Medal by the International Cytokine & Interferon Society (ICIS). Prof. Williams was honored "in recognition of his extraordinary contributions to the cytokine research community," according to an ICIS statement. "The 2019 ICIS Distinguished Service Award acknowledges Williams' commitment to the ICIS and to him being an outstanding ambassador for the Society, in every regard."

"We at the Hope Funds congratulate Dr. Bryan Williams for this distinguished honor," stated Leah Rush Cann, Executive Committee Chair, Hope Funds Board of Trustees.

Professor Williams is Emeritus Director and Distinguished Scientist, Hudson Institute of Medical Research, Professor, Department of Molecular and Translational Science, Monash University in Melbourne, Australia. A distinguished researcher and international authority on innate immunity and cancer biology, he has made major contributions to our understanding of the antiviral mechanisms of actions of interferons, advancing their therapeutic utility. His discoveries in the 2-5A-RNaseL pathway, cloning and characterization of protein kinase R, and innate immune signaling pathways have opened new therapeutic opportunities.

The award was presented on October 20th at Hofburg Palace in Vienna, where Dr. Williams (right) is shown receiving the award from Prof. Kate Fitzgerald of the University of Massachusetts.



About Bryan R.G. Williams, PhD

Professor Williams is a distinguished researcher and international authority on innate immunity and cancer biology. He received his PhD from the Department of Microbiology at the University of Otago, Dunedin, New Zealand. Following postdoctoral training at the National Institute for Medical Research, Mill Hill, London, he held faculty positions at the University of Toronto and the Hospital for Sick Children, Toronto, Canada. He was Chairman of the Department of Cancer Biology at the Lerner Research Institute, Cleveland Clinic, USA, before joining the Monash Institute of Medical Research (MIMR) as Director. He is currently Director and CEO of the Hudson Institute of Medical Research, created by the merging of MIMR with Prince Henry's Institute. Professor Williams is an Honorary Fellow of the Royal Society of New Zealand. He is a Fellow of the American Academy of Microbiology and a Fellow of the Australian Academy of Science.

About the International Cytokine & Interferon Society

Established in 1988, the International Cytokine Society (ICS) consisted of persons who had research, clinical or educational experience in the field of cytokines or in an allied discipline. The

main purposes of the Society was to promote original research in the fields of cytokines, growth factors and receptors and to facilitate communication and interaction between scientists aimed at the multidisciplinary integration of current basic and clinical knowledge and concepts in the study of cytokines. After many years of holding joint meetings with the International Society for Interferon and Cytokine Research (ISICR), the ICS merged with the ISICR to become the International Cytokine & Interferon Society (ICIS) in 2013.

About Hope Funds for Cancer Research

The Hope Funds for Cancer Research was formed in 2006 by a group of concerned individuals who have experience in oncology, intellectual property law, investment banking, philanthropy, sociology, and the arts to establish a funding vehicle that would take a rational scientific, medical, and investment approach to granting money to the most interesting and promising research efforts to address the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, and ovarian cancers, and rare lymphomas, leukemias and MDS. These cancers are insidiously aggressive illnesses that kill most of their victims within months, even with aggressive chemotherapy. The Trustees of the Hope Funds for Cancer Research believe that funding research that could lead to breakthroughs in these areas and increase life expectancy in these types of cancers is at the core of our mission. The Hope Funds for Cancer Research is a 509 (a)(1) charity under 501(c)(3) of the Internal Revenue Service's code. For additional information about the organization, please visit <http://www.Hope-Funds.org> or call 401-847-3286.

Hope Funds for Cancer Research: Advancing Innovative Research in Understudied Cancers

[To visit our website, click here](#)



-END-

11/10/19 - 13